Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon

Immun Inflamm Dis. 2018 Jun;6(2):207-220. doi: 10.1002/iid3.208. Epub 2018 Jan 3.

Abstract

Introduction: A proliferation-inducing ligand (APRIL) and B cell activation factor (BAFF) are known to play a significant role in the pathogenesis of several diseases, including BAFF in malaria. The aim of this study was to investigate whether APRIL and BAFF plasma concentrations could be part of inflammatory responses associated with P. vivax and P. falciparum malaria in patients from the Brazilian Amazon.

Methods: Blood samples were obtained from P. vivax and P. falciparum malaria patients (n = 52) resident in Porto Velho before and 15 days after the beginning of treatment and from uninfected individuals (n = 12). We investigated APRIL and BAFF circulating levels and their association with parasitaemia, WBC counts, and cytokine/chemokine plasma levels. The expression levels of transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) on PBMC from a subset of 5 P. vivax-infected patients were analyzed by flow cytometry.

Results: APRIL plasma levels were transiently increased during acute P. vivax and P. falciparum infections whereas BAFF levels were only increased during acute P. falciparum malaria. Although P. vivax and P. falciparum malaria patients have similar cytokine profiles during infection, in P. vivax acute phase malaria, APRIL but not BAFF levels correlated positively with IL-1, IL-2, IL-4, IL-6, and IL-13 levels. We did not find any association between P. vivax parasitaemia and APRIL levels, while an inverse correlation was found between P. falciparum parasitaemia and APRIL levels. The percentage of TACI positive CD4+ and CD8+ T cells were increased in the acute phase P. vivax malaria.

Conclusion: These findings suggest that the APRIL and BAFF inductions reflect different host strategies for controlling infection with each malaria species.

Keywords: APRIL/BAFF; TACI; malaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimalarials / therapeutic use
  • B-Cell Activating Factor / blood*
  • B-Cell Activating Factor / immunology
  • Brazil
  • Case-Control Studies
  • Drug Therapy, Combination / methods
  • Female
  • Healthy Volunteers
  • Host-Parasite Interactions / immunology
  • Humans
  • Interleukins / blood
  • Interleukins / immunology
  • Leukocyte Count
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Malaria / blood*
  • Malaria / drug therapy
  • Malaria / parasitology
  • Malaria, Falciparum / blood*
  • Malaria, Falciparum / drug therapy
  • Malaria, Falciparum / parasitology
  • Malaria, Vivax / blood*
  • Malaria, Vivax / drug therapy
  • Malaria, Vivax / parasitology
  • Male
  • Parasitemia / immunology
  • Parasitemia / parasitology
  • Plasmodium falciparum / immunology
  • Plasmodium vivax / immunology
  • Transmembrane Activator and CAML Interactor Protein / immunology
  • Transmembrane Activator and CAML Interactor Protein / metabolism
  • Tumor Necrosis Factor Ligand Superfamily Member 13 / blood*
  • Tumor Necrosis Factor Ligand Superfamily Member 13 / immunology
  • Young Adult

Substances

  • Antimalarials
  • B-Cell Activating Factor
  • Interleukins
  • TNFRSF13B protein, human
  • TNFSF13 protein, human
  • TNFSF13B protein, human
  • Transmembrane Activator and CAML Interactor Protein
  • Tumor Necrosis Factor Ligand Superfamily Member 13

Supplementary concepts

  • Acute malaria